Antibody-drug conjugate (ADC)technology is not new. The first ADC, Pfizer Inc.’s Mylotarg, reached the market two decades ago. The field has undergone slow but transformative enhancements.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?